TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer [TH versus THL]
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2018
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TH v THL
- 23 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 23 Jul 2018 Status changed from discontinued to active, no longer recruiting.
- 20 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov